Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 9,120.00
-560.00 (-5.79%)
Mar 23, 2026, 3:30 PM KST
Prestige BioPharma Cash Flow Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Income | 13,676 | 22,297 | -32,921 | 17,569 | -211,450 | -7,391 |
Depreciation & Amortization | 21,801 | 21,801 | 16,267 | 11,650 | 3,867 | 1,667 |
Loss (Gain) From Sale of Assets | 6.7 | 6.7 | -89.4 | -55.17 | -266.37 | 0.36 |
Asset Writedown & Restructuring Costs | -59,462 | -59,462 | - | 15,114 | 72,607 | - |
Loss (Gain) From Sale of Investments | - | - | - | 693.39 | 18,966 | -15,081 |
Stock-Based Compensation | 470.11 | 470.11 | 52.41 | 1,943 | 3,774 | 2,955 |
Provision & Write-off of Bad Debts | - | - | -33.31 | -70,640 | - | - |
Other Operating Activities | -2,672 | -31,684 | -42,356 | -17,826 | 85,640 | 330.51 |
Change in Accounts Receivable | -228.75 | -228.75 | 674.94 | -1,050 | - | - |
Change in Inventory | -4,764 | -4,764 | 7,752 | -10,038 | -24,041 | - |
Change in Accounts Payable | 4,196 | 4,196 | 2,459 | -316.4 | 1,641 | - |
Change in Unearned Revenue | -310.36 | -310.36 | -5.21 | -660.52 | 564.62 | 578.1 |
Change in Other Net Operating Assets | -4,456 | -4,456 | 172.41 | -6,658 | 2,791 | 1,495 |
Operating Cash Flow | -31,744 | -52,135 | -48,027 | -60,274 | -45,907 | -15,446 |
Capital Expenditures | -34,936 | -40,742 | -20,063 | -48,363 | -56,429 | -949.11 |
Sale of Property, Plant & Equipment | 100.24 | 94.2 | 51.21 | 1,133 | 26,428 | - |
Divestitures | - | - | - | 40,039 | - | - |
Sale (Purchase) of Intangibles | -6,850 | -6,028 | -7,463 | -17,254 | -11,684 | -17,162 |
Investment in Securities | 52,916 | -53,291 | 159,987 | -133,827 | -25,239 | - |
Other Investing Activities | -2,047 | -1,840 | -46.85 | 9,662 | 12,555 | -2,801 |
Investing Cash Flow | 9,184 | -101,806 | 132,465 | -148,610 | -184,685 | -20,912 |
Long-Term Debt Issued | - | 53,319 | - | 55,772 | - | 2,769 |
Long-Term Debt Repaid | - | -5,474 | -2,771 | -2,589 | -4,504 | -895.88 |
Net Debt Issued (Repaid) | -67,068 | 47,846 | -2,771 | 53,183 | -4,504 | 1,873 |
Issuance of Common Stock | 1,117 | 1,117 | 1,307 | - | - | 466,094 |
Other Financing Activities | 1,113 | 901.41 | - | - | - | -13,450 |
Financing Cash Flow | -64,838 | 49,864 | -1,464 | 53,183 | -4,504 | 454,517 |
Foreign Exchange Rate Adjustments | 5,573 | 1,850 | 608.72 | 6,888 | -3,177 | -277.54 |
Miscellaneous Cash Flow Adjustments | 0 | - | -0 | 0 | 0 | 0 |
Net Cash Flow | -81,825 | -102,228 | 83,582 | -148,813 | -238,273 | 417,880 |
Free Cash Flow | -66,680 | -92,877 | -68,091 | -108,636 | -102,336 | -16,396 |
Free Cash Flow Margin | -350.52% | -648.33% | -9881.47% | -67125.45% | - | - |
Free Cash Flow Per Share | -1108.78 | -1542.04 | -1135.49 | -1807.71 | -1702.88 | -317.73 |
Cash Interest Paid | 4,206 | 10,742 | 6,082 | 1,834 | 436.07 | 477.47 |
Cash Income Tax Paid | 27.6 | -37.32 | -179.73 | 796.41 | 591.82 | 34.08 |
Levered Free Cash Flow | -70,427 | -122,563 | -46,364 | -23,046 | -114,523 | -22,341 |
Unlevered Free Cash Flow | -65,660 | -117,797 | -41,736 | -22,451 | -114,511 | -22,337 |
Change in Working Capital | -5,563 | -5,563 | 11,053 | -18,723 | -19,044 | 2,073 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.